Company
Every investor coverage indicates participated in a round Azura raised.
Companies Azura acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Azura. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Archangel Ventures' annual review recounts closing its second fund above $32 million, passing $10 million invested in Australian startups, and portfolio raises by Aerotruth, Bare, Trendspek, Pearler and Vively during 2022.
Also Startup Daily·SmartCompany·Startup Daily·Startup Daily·Forbes Australia
Brandon Capital's Medical Research Commercialisation Fund has launched its fifth vehicle, MRCF5, completing a NZ$224 million first close and targeting NZ$267 million, while recalling earlier portfolio exits of Elastagen, Spinifex and Fibrotech.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Startup Daily